SAM
ABBV icon

S.A. Mason’s AbbVie ABBV Stock Holding History

S.A. Mason’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.66M Buy
12,233
+191
+2% +$42.4K 1% 21
2025
Q4 		$2.75M Sell
12,042
-146
-1% -$33.3K 1.09% 19
2025
Q3 		$2.82M Sell
12,188
-99
-0.8% -$20.2K 1.25% 15
2025
Q2 		$2.28M Sell
12,287
-2
-0% -$372 1.1% 16
2025
Q1 		$2.57M Sell
12,289
-456
-4% -$88.6K 1.36% 13
2024
Q4 		$2.26M Buy
12,745
+104
+0.8% +$19.1K 1.19% 14
2024
Q3 		$2.5M Buy
12,641
+18
+0.1% +$3.36K 1.32% 13
2024
Q2 		$2.17M Buy
12,623
+336
+3% +$55.7K 1.23% 14
2024
Q1 		$2.24M Buy
12,287
+20
+0.2% +$3.45K 1.35% 13
2023
Q4 		$1.9M Sell
12,267
-83
-0.7% -$12.1K 1.27% 13
2023
Q3 		$1.84M Sell
12,350
-548
-4% -$80.4K 1.33% 14
2023
Q2 		$2.06M Hold
12,898
– – 1.49% 12
2023
Q1 		$2.06M Buy
12,898
+214
+2% +$32.7K 1.49% 12
2022
Q4 		$2.05M Sell
12,684
-36
-0.3% -$5.52K 1.54% 11
2022
Q3 		$1.71M Sell
12,720
-171
-1% -$24.5K 1.35% 11
2022
Q2 		$1.97M Buy
12,891
+45
+0.4% +$6.88K 1.44% 11
2022
Q1 		$2.08M Buy
12,846
+556
+5% +$80.8K 1.3% 12
2021
Q4 		$1.66M Buy
12,290
+16
+0.1% +$1.89K 1% 19
2021
Q3 		$1.32M Buy
12,274
+738
+6% +$84.3K 0.87% 25
2021
Q2 		$1.3M Sell
11,536
-2
-0% -$225 0.89% 27
2021
Q1 		$1.25M Sell
11,538
-16
-0.1% -$1.71K 0.93% 24
2020
Q4 		$1.24M Sell
11,554
-92
-0.8% -$8.84K 1.03% 20
2020
Q3 		$1.02M Buy
11,646
+8
+0.1% +$753 0.97% 29
2020
Q2 		$1.14M Buy
11,638
+8
+0.1% +$704 1.2% 15
2020
Q1 		$886K Sell
11,630
-66
-0.6% -$5.62K 1.08% 20
2019
Q4 		$1.04M Buy
+11,696
New +$971K 0.99% 24

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

S.A. Mason's ABBV Position: Q1 2026 in Review

S.A. Mason increased its AbbVie (ABBV) stake by 1.6% in Q1 2026, buying an estimated $42.4K and bringing the position to 12,233 shares worth $2.66M. The position accounts for 1% of the portfolio, ranked #21.

S.A. Mason first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. The position peaked at $2.82M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • S.A. Mason held 12,233 shares of AbbVie worth $2.66M as of Q1 2026.
  • S.A. Mason bought 191 AbbVie shares in Q1 2026, an estimated $42.4K.
  • AbbVie made up 1% of S.A. Mason's portfolio in Q1 2026, its #21 holding.
  • S.A. Mason first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • S.A. Mason's AbbVie position peaked at $2.82M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on S.A. Mason's 13F filing for Q1 2026, filed 27 Apr 2026.